The effect of the steroidal androgen receptor antagonist, Win 49,596, on the prostate and testis of beagle dogs.
The effect of the steroidal androgen receptor antagonist Win 49,596 on the prostate and testis was studied in beagle dogs and was compared to the effects of the nonsteroidal androgen receptor antagonist ICI 176,334 and the steroidal 5 alpha-reductase inhibitor MK-906. Win 49,596 was shown to bind to the androgen receptor from normal canine prostate with a Ki of 2.2 microM. After 16 weeks of treatment, prostate size, as estimated by transrectal ultrasonography, was unchanged in intact controls and was 26% of the initial size in castrate controls. Oral doses of Win 49,596 from 0.625-40 mg/kg.day for 16 weeks caused dose-dependent prostatic regression and a dose-related increase in both the incidence and severity of glandular atrophy of the prostate. Prostatic secretory function was also inhibited by Win 49,596 treatment. The effects of Win 49,596 at 40 mg/kg.day on prostatic weight, total DNA, histomorphology, and secretory function were similar to those of castration, while the effects of Win 49,596 at 10 mg/kg.day were similar to those of ICI 176,334 at 0.25 mg/kg.day and MK-906 at 1.0 mg/kg.day. No effects on testicular weight, daily sperm production, or spermatogenesis were observed; however, mild Leydig cell hyperplasia was observed in two dogs treated with 40 mg/kg.day Win 49,596. In addition, at 10 and 40 mg/kg.day Win 49,596, moderate but variable increases in serum testosterone levels were observed. In summary, Win 49,596 caused regression of the hypertrophic canine prostate without effects on spermatogenesis and/or sexual function, supporting its possible use in the treatment of human benign prostatic hypertrophy/hyperplasia.
Department of Pharmacology, Sterling Research Group, Rensselaer, New York 12144.
P E
PE
Juniewicz
M
M
McCarthy
B M
BM
Lemp
T A
TA
Barbolt
C
C
Shaw
D M
DM
Hollenbaugh
R C
RC
Winneker
J R
JR
Reel
F H
FH
Batzold
D058891:5-alpha Reductase Inhibitors; D000726:Androgen Antagonists / Q000378:metabolism; D000736:Androstenes / Q000378:metabolism / Q000494:pharmacology; D000813:Anilides / Q000378:metabolism / Q000494:pharmacology; D000818:Animals; D001378:Azasteroids / Q000378:metabolism / Q000494:pharmacology; D004247:DNA / Q000378:metabolism; D004285:Dogs; D018120:Finasteride; D006984:Hypertrophy; D008297:Male; D009570:Nitriles; D009919:Orchiectomy; D009929:Organ Size / Q000187:drug effects; D011278:Pregnanes / Q000378:metabolism / Q000494:pharmacology* / Q000627:therapeutic use; D011467:Prostate / Q000187:drug effects* / Q000473:pathology / Q000503:physiopathology; D011470:Prostatic Hyperplasia / Q000188:drug therapy*; D011720:Pyrazoles / Q000378:metabolism / Q000494:pharmacology* / Q000627:therapeutic use; D011944:Receptors, Androgen / Q000187:drug effects* / Q000502:physiology; D012661:Semen / Q000378:metabolism; D013091:Spermatogenesis / Q000187:drug effects; D013737:Testis / Q000187:drug effects* / Q000503:physiopathology; D013739:Testosterone / Q000097:blood; D014105:Tosyl Compounds; D014463:Ultrasonography
D058891:5-alpha Reductase Inhibitors; D000726:Androgen Antagonists; D000736:Androstenes; D000813:Anilides; D001378:Azasteroids; D009570:Nitriles; D011278:Pregnanes; D011720:Pyrazoles; D011944:Receptors, Androgen; D014105:Tosyl Compounds; D013739:Testosterone; D018120:Finasteride; D004247:DNA; C053541:bicalutamide; C060492:zanoterone